Core Insights - The IVD (in vitro diagnostics) industry is experiencing a wave of product deregistration, indicating a significant shift in the market dynamics from a "license dividend" era to a "refined cultivation" era [1][4][5] Group 1: Industry Trends - The Zhejiang Provincial Drug Administration announced the cancellation of five medical device registration certificates for Zhejiang Jukang Biological Engineering Co., marking the second mass deregistration in the IVD sector this year [1] - Other provinces, including Anhui, Jiangxi, Guangdong, and Hunan, have also initiated similar deregistration processes, with a total of 99 products deregistered in Hunan alone [2][3] - The number of IVD registration certificates in Hunan surged from 3,066 to 8,889 between 2020 and 2023, reflecting a compound annual growth rate of 30.49% [2] Group 2: Financial Implications - The average price of fluorescent immunoassay products dropped by 25% in the first half of 2023 compared to the previous year, leading to a significant reduction in profit margins from 60%-70% to 30%-40% [4] - The average price reduction for tumor markers and thyroid function tests exceeded 50% in a recent procurement round, severely impacting profit margins for companies [5] - The annual maintenance cost for a single IVD registration certificate ranges from 80,000 to 120,000 yuan, with companies like Derong Biological facing over 6.6 million yuan in maintenance fees for 83 certificates, which is 3.9% of their projected 2024 revenue of 170 million yuan [5] Group 3: Strategic Shifts - Companies are increasingly opting to deregister less competitive products to concentrate resources on core products with greater market potential and technological barriers [5][6] - The industry is urged to enhance technological innovation and focus on core products for sustainable long-term development [6]